Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US

Kamal Chamoun, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Rita Assi, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Farhad Ravandi, MD, Nitin Jain, MD, Naval Daver, MD, Marina Konopleva, MD PhD, Courtney D DiNardo, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1923.

https://doi.org/10.1182/blood.V128.22.1923.1923

Published: 2016

Journal Articles

Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Marina Konopleva, MDPhD, Gautam Borthakur, MD, William G. Wierda, MD PhD, Naval Daver, MD, Koichi Takahashi, MD, Preetesh Jain, MBBS,MDDM,PhD, Jeffrey Skinner, Mary Beth Rios, RN, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 940.

https://doi.org/10.1182/blood.V128.22.940.940

Published: 2016

Journal Articles

Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Farhad Ravandi, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Naval Daver, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Preetesh Jain, MBBS, MDDM, PhD, Mary Beth Rios, RN, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1224.

https://doi.org/10.1182/blood.V128.22.1224.1224

Published: 2016

Journal Articles

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Ohad Benjamini, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Elias Jabbour, MD, Susan O'Brien, M.D., Preetesh Jain, MD, DM, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3783.

https://doi.org/10.1182/blood.V120.21.3783.3783

Published: 2012

Journal Articles

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Hun Lee, MD, Jorge E. Cortes, Susan O'Brien, MD, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, MD, Jenny Shan, PhD, Mary Beth Rios, RN, Farhad Ravandi, MD, Stefan Faderl, MD, Tapan Kadia, Gautam Borthakur, Xuelin Huang, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2750.

https://doi.org/10.1182/blood.V118.21.2750.2750

Published: 2011

Journal Articles

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Susan o'Brien, Deborah A. Thomas, MD, Maro Ohanian, M.D., Jeffrey L. Jorgensen, MD, PhD, Partow Kebriaei, MD, Elias Jabbour, Michael E. Rytting, MD, Sergernne York, RN, Farhad Ravandi, MD, Monica Kwari, BSN, Stefan Faderl, MD, Mary Beth Rios, RN, Jorge E. Cortes, Luis Fayad, MD, Robert Tarnai, MT, Sa A. Wang, MD, Richard Champlin, MD, Anjali S. Advani, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 875.

https://doi.org/10.1182/blood.V118.21.875.875

Published: 2011

Journal Articles

Phase I Study of Bendamustine in Refractory Leukemia.

Mary Beth Rios, RN, Elias Jabbour, MD, Farhad Ravandi, M.D., Tapan Kadia, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Elizabeth Burton, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4156.

https://doi.org/10.1182/blood.V114.22.4156.4156

Published: 2009

Journal Articles

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Elias Jabbour, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Jenny Shan, PhD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Farhad Ravandi, MD, Gautam Borthakur, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 509.

https://doi.org/10.1182/blood.V114.22.509.509

Published: 2009

Journal Articles

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Dushyant Verma, MD, FACP, Hagop M Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Amit Verma, MD, Elias Jabbour, MD, Srdan Verstovsek, MD, PhD, Tapan Kadia, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 505.

https://doi.org/10.1182/blood.V114.22.505.505

Published: 2009

Journal Articles

Upregulation of CXCR4 Is Essential for the Migration and Survival of Quiescent CML Progenitor Cells in the Bone Marrow Microenvironment after Imatinib Treatment.

Yoko Tabe, MD, PhD, Linhua Jin, BA, Sergej Konoplev, MD, PhD, Lu Hongbo, MMSC, Shinya Kimura, MD, PhD, Mary-Beth Rios, RN, Hagop M. Kantarjian, PhD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2007) 110 (11): 1004.

https://doi.org/10.1182/blood.V110.11.1004.1004

Published: 2007

Journal Articles

Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop Kantarjian, MD, Jenny Shan, Susan O’Brien, MD, William Wierda, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Steven Kornblau, MD, Brenda K. Walker, RN, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2007) 110 (11): 1942.

https://doi.org/10.1182/blood.V110.11.1942.1942

Published: 2007

Journal Articles

Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI).

Carmen Fava, MD, Hagop M. Kantarjian, MD, Elias Jabbour, MD, Mary Beth Rios, RN, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Jorge Cortes, MD

Blood (2007) 110 (11): 1944.

https://doi.org/10.1182/blood.V110.11.1944.1944

Published: 2007

Journal Articles

Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Novel Tyrosine Kinase Inhibitors (NTKI) Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) after Imatinib-Failure.

Elias Jabbour, MD, Hagop Kantarjian, MD, Lynne Abruzzo, MD, Francis Giles, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2006) 108 (11): 2115.

https://doi.org/10.1182/blood.V108.11.2115.2115

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CML Patients Outcome after TKI Discontinuation: A Single Institution Experience in the US

Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase

Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)

Phase I Study of Bendamustine in Refractory Leukemia.

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Upregulation of CXCR4 Is Essential for the Migration and Survival of Quiescent CML Progenitor Cells in the Bone Marrow Microenvironment after Imatinib Treatment.

Prognostic Significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs).

Long-Term Significance of Achieving a Major Cytogenetic Response (MCyR) without a Complete Hematologic Response (CHR) among Patients (pts) with Chronic Myeloid Leukemia (CML) in Advanced Phase Treated with Second Generation Tyrosine Kinase Inhibitors (TKI).

Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Novel Tyrosine Kinase Inhibitors (NTKI) Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) after Imatinib-Failure.

Email alerts

ASH Publications

American Society of Hematology